Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. iX Biopharma's annualizedNet Income for the quarter that ended in Dec. 2023 was S$-14.66 Mil. iX Biopharma's average total tangible assets for the quarter that ended in Dec. 2023 was S$21.32 Mil. Therefore, iX Biopharma's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -68.75%.
The historical rank and industry rank for iX Biopharma's Return-on-Tangible-Asset or its related term are showing as below:
SGX:42C'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -72.71 Med: -31.61 Max: -10.24
Current: -42.24
During the past 10 years, iX Biopharma's highest Return-on-Tangible-Asset was -10.24%. The lowest was -72.71%. And the median was -31.61%.
SGX:42C's Return-on-Tangible-Asset is ranked worse than 81.9% of 1083
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs SGX:42C: -42.24
iX Biopharma Return-on-Tangible-Asset Historical Data
The historical data trend for iX Biopharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of iX Biopharma's Return-on-Tangible-Asset
For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iX Biopharma's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where iX Biopharma's Return-on-Tangible-Asset falls into.
iX Biopharma Return-on-Tangible-Asset Calculation
iX Biopharma's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2023) net income data.
iX Biopharma (SGX:42C) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
iX Biopharma Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of iX Biopharma's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGX:42C has been successfully added to your 